Note: The U.S. FDA has not evaluated these statements. No product offered for sale at vitalchoice.com is intended to diagnose, treat, cure or prevent any disease.
- Omega-3s from land and sea: A key distinction
- Long-chain omega-3s: Truly essential to life and health
- Omega-3 EPA and DHA: Key heart-health allies
- How much omega-3 EPA and DHA do you need?
- Safety considerations & Further reading
- Primary Sources
To survive and thrive, humans need to consume small amounts of two kinds of polyunsaturated fat, called omega-3 fatty acids and omega-6 fatty acids.
We cannot make omega-3 and omega-6 fatty acids in our bodies, so we have to get them from foods or supplements.
The average American gets too many omega-6 fatty acids, primarily from the vegetable oils used in home kitchens and in almost all restaurant, take-out, prepared, and packaged foods.
In fact, most Americans consume omega-6s to unhealthful excess ... a subject covered in "America's Sickening Omega Imbalance" and "Know Your Omega-3/6 Numbers". This imbalance is the subject of our "Out of Balance" video, featuring top researchers in the field.
In contrast, most Americans don't get enough omega-3 fatty acids to enable and maintain optimal health …in part because of their over-consumption of omega-6 fatty acids.
Note: While wild and farmed salmon have comparable levels of omega-3s, farmed salmon is generally much higher in omega-6 fats.
This imbalance between omega-3 and omega-6 fats in the average American's diet led us to offer a state-of-the-art home test, called "The Vital Omega-3 and 6 HUFA Test™".
- Back to top -
2. Omega-3s from land and sea: A key distinction
Omega-3 fatty acids come in two basic forms, with distinctly different health impacts:
- Short-chain (polyunsaturated) omega-3 ALA from plant foods.
- Long-chain (highly unsaturated) omega-3s (EPA and DHA) from seafood and fish oil.
The body only needs EPA and DHA, very small amounts of which it can make from plant-source ALA.
Of the three omega-3s, DHA is by far the most important one to get from foods or supplements, for these reasons:
- The body can make modest amounts of EPA from dietary ALA.
- Most people do not convert dietary EPA into substantial amounts of DHA.
- Less than 10 percent of the EPA made from ALA gets converted into DHA.
- Most people convert less than one half of one percent of dietary ALA into DHA.
On average, people convert about five percent of the ALA they get from plant foods or oils into long-chain omega-3s — almost entirely EPA. (Most of the ALA we consume is oxidized or "burned" for energy.)
This conversion rate ranges from one to 10 percent, and varies by your gender, genetic profile, and overall diet.
There are important exceptions to this rule:
- Pregnant and nursing women convert larger amounts of dietary ALA into EPA and DHA (about 10 percent, versus one to five percent in their peers).
- People who eat little or no fish take no fish oils rich in EPA and DHA (such as vegans) convert larger amounts of dietary ALA into EPA and DHA, compared with people who routinely ingest significant amounts of EPA and DHA.
Recent findings revealed genetic variations that greatly affect the conversion of short-chain, plant-source omega-3s and omega-6s into their long-chain, animal-source forms ... with large differences seen among various geographical regions ... see "Dramatic Omega-3 Discovery".
That highlights the value of blood testing to monitor your omega-3/omega-6 balance.
High omega-6 intakes limit conversion of ALA into omega-3 EPA and DHA
Your intake of the short-chain omega-6 fatty acid called LA — concentrated in nuts, most seeds, and cheap vegetable oils — exerts a big influence on the conversion of ALA into EPA and DHA.
This is because short-chain omega-6 LA competes with short-chain omega-3 ALA for the body's limited capacity to convert these short-chain fatty acids into their long-chain forms.
Short-chain omega-3s: Necessary only in diets lacking fish fat
Certain plant foods and vegetable oils contain small amounts of short-chain omega-3 ALA (alpha-linolenic acid).
Your body does not need short-chain omega-3 ALA … unless your diet lacks long-chain omega-3 EPA and DHA, in which case it can make very small amounts from dietary ALA.
However, the body makes much more EPA than DHA from ALA, which means that plant foods providing ALA are very poor sources of DHA.
Only one to 10 percent of dietary ALA gets converted to EPA, and only about 0.5 percent of dietary ALA gets converted to DHA … and the body makes very little DHA from dietary EPA.
The body converts from one to 10 percent of dietary ALA into EPA and DHA, with vegans, vegetarians, and women — especially pregnant and nursing women — showing the highest conversion rates.
Vegan and vegetarian diets normally contain no EPA or DHA, because such diets lack any seafood or DHA-fortified animal foods (e.g., special DHA-rich eggs).
Accordingly, vegans and vegetarians must either consume plant foods containing omega-3 ALA — from which their bodies will produce EPA and DHA — or take supplements containing DHA from algae, some of which their bodies will use to make EPA.
These are common sources of ALA, listed in rough order, from most to least ALA content:
Flaxseed oil, walnuts, flaxseed, walnut oil, canola oil, soybeans, soybean oil*, hemp seed, hemp oil, leafy green vegetables (purslane, grape leaves, spinach, kale, chard, collards), cauliflower, radish sprouts, beans, broccoli, Brussels sprouts, seaweed, and green or yellow squash.
*Note: Most soy oil sold in the U.S. is abnormally low in omega-3 ALA. It comes from soybeans modified to reduce their ALA content so as to extend the shelf life of the oil extracted from them. And it’s very high in competing omega-6 fats.
- Back to top -
Omega-3 EPA and DHA are essential to life itself, and a very large body of evidence indicates that diets rich in both promote optimal health.
Fish, shellfish, zooplankton (e.g., krill), algae, and certain aquatic plants (e.g., seaweed) are the only food sources of EPA and DHA. This explains why EPA and DHA are sometimes called "marine" omega-3s.
Among marine foods, fatty fish like salmon, tuna, sardines, mackerel, herring, anchovies, and sablefish are the richest sources of EPA and DHA, by far.
Here's why omega-3 DHA and EPA are essential to human life and to optimal health:
Omega-3 DHA (docosahexaenoic acid) is also found in almost all cell membranes, and unlike EPA, it plays essential structural and functional roles in the brain, nervous system, and eyes.
- DHA is essential to development of the growing brain.
- DHA is essential to the human brain and nervous system, and to thinking and memory. Brain tissues average 50 percent fatty acids by weight, and DHA averages about 15 percent of those.
- DHA regulates the expression of dozens of "working" genes in the brain, and stimulates growth of the connections between brain cells (neurons).
- DHA is essential to eye structure and functions, and to infants' eye development.
- DHA is the dominant fatty acid in sperm, and is critical to male reproductive health.
- The body uses DHA to make critical inflammation- and oxidation-regulating chemicals.
- DHA moderates the creation of pro-inflammatory eicosanoids from omega-6 fats.
Omega-3 EPA (eicosapentaenoic acid) is found in almost all cells in the body:
- EPA appears to support and promote healthy mood and good mental health.
- The body uses EPA to make ephemeral, hormone-like compounds (prostaglandins, leukotrienes, and thromboxanes) that play key roles in the regulation of inflammation.
- The body uses EPA to make critical inflammation- and oxidation-regulating chemicals.
Note: A third, little-known long-chain omega-3 fatty acid called DPA (docosapentaenoic acid) appears to enhance cardiovascular function and other aspects of health, and is the subject of growing research.
Small amounts of DPA occur in fish, shellfish, and other ocean species. The body can make DPA from EPA, and vice versa. Confusingly, there is also an omega-6 fatty acid called docosapentaenoic acid (DPA).
- Back to top -
The U.S. Agency for Healthcare Research and Quality (AHRQ) is the lead Federal agency charged with supporting research designed to improve the quality of health care, reduce its cost, address patient safety and medical errors, and broaden access to essential services.
In 2003, AHRQ commissioned a group of leading academic researchers to examine the available evidence concerning the impacts of omega-3s from fish (EPA and DHA) and plant foods (ALA) on cardiovascular disease (CVD).
The resulting 2004 AHRQ report — "Effects of Omega-3 Fatty Acids on Cardiovascular Disease" — found ample high-quality evidence for the cardiovascular-health and death-prevention benefits of fish and fish oil, but much less evidence concerning omega-3 ALA in plant foods: "Overall, a number of studies offer evidence to support the hypothesis that fish, fish oil, or ALA supplement consumption reduces all-cause mortality and various CVD outcomes, although the evidence is strongest for fish or fish oil."
This finding was echoed in a 2004 ruling by the U.S. Food and Drug Administration (FDA), in which the agency approved the following qualified health claim for fish and fish oil supplements: "Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease."
The American Heart Association (AHA) agrees with these Federal findings, and says that the long-chain omega-3s from fish fat (EPA and DHA) reduce the risk of cardiovascular disease, thanks to the following effects:
- Moderate blood pressure.
- Promote healthy artery function.
- Lower triglyceride (blood fat) levels.
- Reduce blood stickiness (platelet aggregation).
- Optimize the ratio of HDL to non-HDL cholesterol.
- Help stabilize arterial plaque and inhibit its accumulation.
- Reduce the risk of arrhythmias that can lead to sudden cardiac death.
Omega-3s do not lower total or LDL cholesterol levels, and can in fact raise LDL levels slightly. However, omega-3s also reduce the oxidation of LDL cholesterol and improve the ratio of HDL ("good") cholesterol to non-HDL cholesterol. These two measures are considered more accurate predictors of cardiovascular health risk, compared with total or LDL cholesterol levels.
The AHA makes these recommendations with regard to omega-3s, fish and heart health:
- People without documented coronary heart disease: Enjoy two servings of fish per week.
- Patients with diagnosed coronary heart disease: Consume 1,000 mg (1 gm) of omega-3s daily, preferably from fatty fish or fish oil supplements.
- Patients who need to lower triglycerides: Take 2 to 4 grams (2000 to 4000mg) of omega-3s daily.
- Patients taking more than 3 grams (3000mg) of omega-3s per day from fish oil capsules should do so only under a physician's guidance.
We would add this caution: Persons diagnosed with heart disease — especially those using implanted cardiac defibrillators or taking blood thinning drugs — should consult a physician before taking supplemental omega-3s or any other dietary supplement.
For more information, see "Safety considerations: doses and contraindications", below.
To learn more, visit these American Heart Association pages:
- Back to top -
Most researchers and official bodies recommend these combined amounts of EPA and DHA daily in order to enable optimal health:
- Infants* — 200mg of EPA+DHA per day
- Pregnant/nursing women — 500mg of EPA+DHA per day
- Children aged 12 or younger* — 300mg of EPA+DHA per day.
- Healthy teens and adults — 250-500mg of EPA+DHA per day.
While DHA is the most important, research indicates that it’s best to consume about one to two parts EPA to one part DHA.
Conveniently, most fish, shellfish, and fish oils contain roughly equal amounts of EPA and DHA, though most provide more EPA than DHA.
Unfortunately, the average American consumes only 28-40mg of EPA (average 34mg) and 39-75mg of DHA daily (average 57mg). According to US government surveys, only one in four Americans consumes any EPA or DHA.
An expert panel commissioned by the National Institutes of Health (NIH) recommended 650mg of EPA+DHA per day.
To reach (or closely approach) an intake of 650mg, you could take 4 capsules of 1,000mg Wild Sockeye Salmon Oil, 8 capsules of 500mg Wild Sockeye Salmon Oil, 3 capsules of 1000mg Vital Red Krill Oil, 6 capsules of 500mg Vital Red Krill Oil, 1 capsule of High Potency Omega-3 Therapy, or 1 capsule of High DHA Prenatal Therapy.
These the official intake guidelines issued by the scientific bodies* with the greatest expertise. You could satisfy these recommendations for healthy adults by consuming seafood, supplements, or some combination of the two:
- WHO recommends 250-500mg of omega-3 EPA+DHA per day.
- EFSA recommends 250mg of omega-3 EPA+DHA per day.
- ISSFAL recommends 500mg of omega-3 EPA+DHA per day (at least 220mg of DHA and 220mg of EPA).
- IOM recommends 130-260mg of omega-3 EPA+DHA per day.
- AHA makes no specific EPA+DHA intake recommendation for healthy people, but advises them to eat at least two servings of fatty seafood per week (e.g., salmon, tuna, sablefish, mackerel, or sardines).
- AHA advises heart patients to take 1000mg (1 gram) of omega-3 EPA+DHA per day, and says that heart patients can lower triglyceride levels as needed under a physician's guidance by taking 2000mg to 4000mg grams of omega-3 EPA+DHA per day.
*UN World Health Organization (WHO) • European Food Safety Agency (EFSA) • International Society for the Study of Fatty Acids and Lipids (ISSFAL) • American Heart Association (AHA) • U.S. Institute of Medicine (IOM)
Daily intakes of EPA+DHA that fall under 3000mg — but exceed the minimum intakes recommended by the AHA and others (250-500mg) — may confer additional health benefits, especially in the context of diets high in competing omega-6 fatty acids.
- Back to top -
Many clinical trials have used doses of 1000mg to 3000mg of EPA+DHA per day, with no adverse effects other than fishy burps or slight stomach upset in some people.
The U.S. FDA has said that it sees no risk from intakes up to 3000mg (3 grams) of EPA+DHA per day, while the American Heart Association recommends doses up to 4000mg per day under a physician's supervision.
In 2012, the European Food Safety Authority (EFSA) concluded that it is safe for adults to consume up to 5 grams (5,000mg) of supplemental omega-3 EPA+DHA per day. The agency did not set an upper intake limit for children.
Specifically, the European experts found that omega-3 intakes of up to 5 grams a day do not increase the risk of bleeding, impaired regulation of glucose levels, or impaired immune function.
To be safe, we suggest that you consult with a physician before taking more than 4,000mg of supplemental omega-3 EPA+DHA per day, especially if you have been diagnosed with a cardiac or immune disorder.
(To reach an intake of 4,000mg of EPA+DHA, you would need to take 26 capsules of 1,000mg Wild Sockeye Salmon Oil, 52 capsules of 500mg Wild Sockeye Salmon Oil, 19 capsules of 1000mg Vital Red Krill Oil, 8 capsules of High Potency Omega-3 Therapy, or 8 capsules of High DHA Prenatal Therapy.)
The omega-3s in fish oil possess properties associated with blood thinning, but — when taken at recommended doses — do not normally pose a risk to persons taking blood-thinning drugs (e.g., coumadin, warfarin, and aspirin) or undergoing surgery: see Can Fish Oil Cause Bleeding Risks? and Omega-3s May Enhance Post-Surgery Outcomes.
- Back to top -
- Back to top -
- Agency for Healthcare Research and Quality. Health Effects of Omega-3 Fatty Acids on Asthma Summary. Evidence Report/Technology Assessment: Number 91. Accessed at http://archive.ahrq.gov/clinic/ epcsums/o3asthsum.htm
- Agency for Healthcare Research and Quality. Effects of Omega-3 Fatty Acids on Cancer. Accessed at http://archive.ahrq.gov/clinic/epcsums/o3cansum.htm
- Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment: Number 94. Effects of Omega-3 Fatty Acids on Cardiovascular Disease. Accessed at http://archive.ahrq.gov/clinic/tp/o3cardtp.htm
- Agency for Healthcare Research and Quality. Omega-3 Fatty Acids and Cardiovascular Disease - Update. Research Protocol — April 2, 2015. Accessed at http://effectivehealthcare.ahrq.gov/ search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=2060
- Agency for Healthcare Research and Quality. Effects of Omega-3 Fatty Acids on Child and Maternal Health. Evidence Report/Technology Assessment Number 118 August 2005. Accessed at http://archive.ahrq.gov/downloads/pub/evidence /pdf/o3maternalchild/o3mch.pdf
- Agency for Healthcare Research and Quality. Omega 3 Fatty Acids and Maternal and Child Health. Research Protocol — May 18, 2015. Accessed at http://effectivehealthcare.ahrq.gov/ search-for-guides-reviews-and-reports/?pageaction=displayProduct&productID=2083
- Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment: Number 116. Effects of Omega-3 Fatty Acids on Mental Health — Summary. Accessed at http://archive.ahrq.gov/clinic/epcsums/o3mentsum.htm
- Bazan NG. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):205-11. Epub 2009 Jun 11. Review.
- Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 2005 Apr;15(2):159-66. Review.
- Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry. 2012 Dec;17(12):1272-82. doi: 10.1038/mp.2011.100. Epub 2011 Sep 20. Review.
- Bouwstra H, Dijck-Brouwer DJ, Decsi T, Boehm G, Boersma ER, Muskiet FA, Hadders-Algra M. Relationship between umbilical cord essential fatty acid content and the quality of general movements of healthy term infants at 3 months. Pediatr Res. 2006 May;59(5):717-22.
- Bouwstra H, Dijck-Brouwer J, Decsi , Boehm G, Boersma ER, Muskiet FA, Hadders-Algra M. Neurologic condition of healthy term infants at 18 months: positive association with venous umbilical DHA status and negative association with umbilical trans-fatty acids. Pediatr Res. 2006 Sep;60(3):334-9. Epub 2006 Jul 20.
- Bradbury J. Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. Nutrients. 2011 May;3(5):529-54. doi: 10.3390/nu3050529. Epub 2011 May 10. Review.
- Brenna JT, Salem N Jr, Sinclair AJ, Cunnane SC; International Society for the Study of Fatty Acids and Lipids, ISSFAL. alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids. 2009 Feb-Mar;80(2-3):85-91. Epub 2009 Mar 9. Review.
- Brenna JT, Diau GY. The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 2007, 77, 247—250
- Calder PC. Long-chain fatty acids and inflammation. Proc Nutr Soc. 2012 Feb 28:1-6. [Epub ahead of print]
- Calder PC. Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie. 2009 Jun;91(6):791-5. Review.
- Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem. 2004 Aug;90(4):979-88. Erratum in: J Neurochem. 2004 Sep;90(6):1540.
- Conquer JA, Martin JB, Tummon I, Watson L, Tekpetey F. Fatty acid analysis of blood serum, seminal plasma, and spermatozoa of normozoospermic vs. asthenozoospermic males. Lipids. 1999 Aug;34(8):793-9.
- Delgado-Noguera MF, Calvache JA, Bonfill Cosp X. Supplementation with long chain polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child growth and development. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD007901. Review.
- Dunstan JA, Mitoulas LR, Dixon G, Doherty DA, Hartmann PE, Simmer K, Prescott SL. The effects of fish oil supplementation in pregnancy on breast milk fatty acid composition over the course of lactation: a randomized controlled trial. Pediatr Res. 2007 Dec;62(6):689-94.
- Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE Jr, Marangell LB, Richardson AJ, Lake J, Stoll AL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry. 2006 Dec;67(12):1954-67. Review.
- Freeman MP. Omega-3 fatty acids in psychiatry: a review. Ann Clin Psychiatry. 2000 Sep;12(3):159-65. Review.
- Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, Drago F, Caraci F Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014 May 7;9(5):e96905. doi: 10.1371/journal.pone.0096905. eCollection 2014.
- Huffman SL, Harika RK, Eilander A, Osendarp SJ. Essential fats: how do they affect growth and development of infants and young children in developing countries? A literature review. Matern Child Nutr. 2011 Oct;7 Suppl 3:44-65. doi: 10.1111/j.1740-8709.2011.00356.x. Review.
- International Society for the Study of Fatty Acids and Lipids (ISSFAL). Report of the Sub-Committee on Recommendation for Intake of Polyunsaturated Fatty Acids in Health Adults. June 2004. Accessed at http://www.issfal.org/news-links/resources/publications/PUFAIntakeReccomdFinalReport.pdf
- Jackson PA, Reay JL, Scholey AB, Kennedy DO. DHA-rich oil modulates the cerebral haemodynamic response to cognitive tasks in healthy young adults: a near IR spectroscopy pilot study. Br J Nutr. 2012 Apr;107 (8):1093-8. doi: 10.1017/S0007114511004041. Epub 2011 Oct 3.
- Kaur G, Cameron-Smith D, Garg M, Sinclair AJ. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog Lipid Res. 2011 Jan;50(1):28-34. Epub 2010 Jul 23. Review.
- Kris-Etherton PM, Harris WS, Appel LJ; AHA Nutrition Committee. American Heart Association. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):151-2. Review.
- Kris-Etherton PM, Innis S, American Dietetic Association, Dietitians of Canada. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc. 2007 Sep;107(9):1599-611. Erratum in: J Am Diet Assoc. 2007 Dec;107(12):2151.
- Liou YA, King DJ, Zibrik D, Innis SM. Decreasing linoleic acid with constant alpha-linolenic acid in dietary fats increases (n-3) eicosapentaenoic acid in plasma phospholipids in healthy men. J Nutr. 2007 Apr;137(4):945-52.
- Megdal PA, Craft NA, Handelman GJ.A simplified method to distinguish farmed (Salmo salar) from wild salmon: fatty acid ratios versus astaxanthin chiral isomers. Lipids. 2009 Jun;44(6):569-76. Epub 2009 May 19.
- Montgomery P, Richardson AJ Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005169. doi: 10.1002/14651858.CD005169.pub2. Review.
- Mozaffarian D, Wu JH. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr. 2012 Mar;142(3):614S-625S. Epub 2012 Jan 25. Review.
- Novak EM, Dyer RA, Innis SM. High dietary omega-6 fatty acids contribute to reduced docosahexaenoic acid in the developing brain and inhibit secondary neurite growth. Brain Res. 2008 Oct 27;1237:136-45. Epub 2008 Aug 5.
- Omega-3 Fatty Acids. Tufts University School of Medicine. Accessed at http://www.tufts.edu/med/nutrition-infection/hiv/health_omega3.html
- Parker G, Gibson NA, Brotchie H, Heruc G, Rees AM, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006 Jun;163(6):969-78. Review. Erratum in: Am J Psychiatry. 2006 Oct;163(10):1842.
- Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs. 2005;65(8):1051-9. Review.
- Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis. 2007 Sep 18;6:21. Review.
- SELF Nutrition Data. Foods highest in Total Omega-3 fatty acids. Accessed at http://nutritiondata.self.com/foods-011140000000000000000.html?maxCount=216
- Simopoulos AP, Leaf A, Salem Jr N. Workshop on the Essentiality of and Recommended Dietary Intakes for (RDI) for Omega-6 and Omega-3 Fatty Acids. The Cloisters, National Institutes of Health (NIH), Bethesda, Maryland, USA, April 7-9, 1999. Accessed at http://www.issfal.org/statements/adequate-intakes-recommendation-table.
- Singh M. Essential fatty acids, DHA and human brain. Indian J Pediatr. 2005 Mar;72(3):239-42. Review.
- Stark DT, Bazan NG.Neuroprotectin D1 induces neuronal survival and downregulation of amyloidogenic processing in Alzheimer's disease cellular models. Mol Neurobiol. 2011 Apr;43(2):131-8. Epub 2011 Mar 10. Review.
- Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999 May;56(5):407-12
- Sublette ME, Ellis SP, Geant AL, Mann JJ Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011 Dec;72(12):1577-84. doi: 10.4088/JCP.10m06634. Epub 2011 Sep 6.
- Tassoni D et al.. The role of eicosanoids in the brain. Asia Pac J Clin Nutr 2008, 17, 220—228.
- Tavilani H, Doosti M, Abdi K, Vaisiraygani A, Joshaghani HR. Decreased polyunsaturated and increased saturated fatty acid concentration in spermatozoa from asthenozoospermic males as compared with normozoospermic males. Andrologia. 2006 Oct;38(5):173-8.
- U.S. Food and Drug Administration. Summary of Qualified Health Claims Subject to Enforcement Discretion. Omega-3 Fatty Acids & Coronary Heart Disease; Docket No. 2003Q-0401. Accessed at here
- Wang C, Chung M, Lichtenstein A, Balk E, Kupelnick B, DeVine D, Lawrence A, Lau J. Effects of Omega-3 Fatty Acids on Cardiovascular Disease. Summary, Evidence Report/Technology Assessment No. 94. (Prepared by the Tufts-New England Medical Center Evidence-based Practice Center, Boston, MA.) AHRQ Publication No. 04-E009-1. Rockville, MD: Agency for Healthcare Research and Quality. March 2004. Accessed at http://www.ahrq.gov/clinic/epcsums/o3cardsum.pdf
- Young G, Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev. 2005 Jan-Feb;45(1):1-28. Review.
- Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR?-mediated mechanisms in Alzheimer's disease models. PLoS One. 2011 Jan 5;6(1):e15816.